Schoolchildren with attention deficit/hyperactivity disorder are substantially more likely to engage in many types of criminal activity such as burglary, theft and drug dealing as they grow older, a new study by the Yale School of Public Health has found. The research was published in The Journal of Mental Health Policy and Economics. An analysis of more than 10, 000 adolescents who were later surveyed as young adults found that children with ADHD were twice as likely to commit theft later in life and had a 50 percent higher incidence of selling drugs. The research results are believed to be the first evidence of a link between illegal activity and the childhood condition commonly known as ADHD that uses a national sample of individuals.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of The Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years. Researcher Dr. Wolff Schlotz points out, "Our findings further support the hypothesis that maternal nutrition contributes to an individuals' development, with potential consequences for their behavior later in life." The long term effects of poor maternal nutrition may even branch out to the child's ability to interact with peers or form social bonds.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder ( ADHD ) treatments, INTUNIV™ (guanfacine) Extended Release Tablets, Vyvanse ® (lisdexamfetamine dimesylate) Capsules CII, and Daytrana® (methylphenidate transdermal system) CII, at a national meeting of psychiatrists being held October 27 - November 1 in Honolulu. "Shire is committed to the advancement of ADHD treatment research and is leading the way in developing a diverse range of safe and effective ADHD treatments, " said Michael Yasick, Senior Vice President of the Shire ADHD Business Unit.
Shire Reports Tolerability And Clinical Effects Results Of Daytrana R methylphenidate Transdermal System From Study In Adolescents With ADHD
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder ( ADHD ). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented. Daytrana, the first and only patch for the treatment of ADHD, is indicated for use in children aged 6 to 12 years with the disorder. Alain Katic, MD, child psychiatrist at the Claghorn Research Clinic in Houston, Texas, states, "In this 6-month, open-label adolescent extension study, we found that most adverse events were generally mild to moderate in intensity.
Objective Measures Of ADHD Symptoms Using The Quotient TM ADHD System May Reduce Cost Of ADHD Drug Trials
BioBehavioral Diagnostics Company announced that its poster was presented Friday, October 30, 2009 after it was accepted via a rigorous peer-review process and included as a New Research Poster presentation at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP) in Honolulu, HI, October 27-November 1, 2009. Calvin R. Sumner, M.D., the company's Chief Medical Officer and Senior Vice President of Clinical Development, presented the study entitled "Does Placebo Response Differ Between Objective and Subjective ADHD Measures?" Placebo response is a well-known phenomenon in ADHD clinical trials, where subjects report benefit when taking an inactive sugar pill.
Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD. "It is important that pupils are offered the support to which they are entitled", says Jakob Asberg in a new thesis at the University of Gothenburg. "Pupils with these neuropsychiatric disorders are often reported as having problems with spoken and written activities. However, relatively little research has been carried out within the field. Considering how important such skills are for coping independently in school and in working life and society in general, it is of great importance that we become better informed about these issues", considers Jakob Ã.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder ( ADHD ) in children and adolescents ages 6 to 17. INTUNIV, a once-daily formulation of guanfacine, is the first and only nonscheduled alpha-2A receptor agonist approved for the treatment of ADHD. In clinical trials, INTUNIV provided significant efficacy across the spectrum of ADHD symptoms that can be disruptive, such as being easily distracted, interrupting others, running around excessively, arguing with adults, and losing temper.
Shire Reports Findings From An Analysis Examining Emotional Lability In Children With ADHD Taking Vyvanse R lisdexamfetamine Dimesylate Capsules
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse ® . In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder ( ADHD ) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.
Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics. A professor in Queen's School of Policy Studies and Department of Economics, Dr. Lehrer shares the RAND Corporation's Victor R. Fuchs Research Award with Jason Fletcher of Yale University. Their prize-winning paper, recently published in the journal Forum for Health Economics & Policy, examines the effects of adolescent health on educational outcomes. "Our study shows that poor mental health in children and teenagers has a large impact on the length of time they will stay in school, " says Dr. Lehrer. He notes a large number of school-based programs have recently been introduced to prevent childhood obesity through lifestyle changes, but suggests the net should be cast more widely.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse ® . In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder ( ADHD ) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.